Ludwig Kappos from University of Basel: Siponimod Shows Promise for Secondary Progressive Multiple Sclerosis

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

Ludwig Kappos, MD, from the University of Basel discussed what could be a breakthrough treatment for siponimod at the annual ECTRIMS conference in London. Kappos said that while the medication is not a final step in the treatment of the condition, it is a solid first step to help patients that until now did not have a new treatment option on the horizon.